Acadia Pharma: (NASD: ACAD)
$14.15
0.88 (6.63%)
Volume 6,845,904
May 20 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 13.40 - 14.75 |
| 52wk Low - High | 1.30 - 14.75 |
| Previous Close | 13.27 |
| Avg. Volume | 3,707,947 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 1.11 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 2.89 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.35 |
| Quarterly Earnings ESP |
-12.50% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.35 |
| Current Quarter Estimate | -0.08 |
| Most Accurate Estimate | -0.09 |
| Earnings ESP |
-12.50% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -0.33 |
| Expected Earnings Growth | NA |
Company Description
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.08 | -0.09 | -0.35 | -0.10 |
| Number of Estimates | 4 | 5 | 5 | 5 |
| Low Estimate | -0.09 | -0.11 | -0.40 | -0.45 |
| High Estimate | -0.08 | -0.08 | -0.32 | NA |
| Year Ago EPS | -0.10 | -0.04 | -0.38 | -0.35 |
| EPS Growth | 17.50% | -130.00% | 7.37% | 70.45% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ACADIA PHARMA | ACAD | 14.15 | |
|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 14.39 | |
|
| GENTIUM SPA-ADR | GENT | 8.84 | |
|
| AASTROM BIOSCI | ASTM | 0.59 | |
|
| ACHILLION PHARM | ACHN | 7.55 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.27 | |
|
| ALEXION PHARMA | ALXN | 100.03 | |
|
| ALKERMES INC | ALKS | 31.04 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -0.33 |
| Sales | 5 |
| Net Income | -21 |
| Price/Earnings | NA |
| Price/Book | 13.12 |
| Price/Cash Flow | NA |
| Price/Sales | 214.74 |
News
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock - Benzinga
May 20, 2013
Mid-Morning Market Update: Markets Fall, Yahoo To Acquire Tumblr - Benzinga
May 20, 2013
5 of Last Week`s Biggest Winners - TheMotleyFool
May 19, 2013
Too Many Questions Make This Thursday Mover a Sell - TheMotleyFool
May 19, 2013
U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying - Benzinga
May 18, 2013
This Stock Should Get Better in the Long Run - TheMotleyFool
May 15, 2013
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock - Benzinga
May 14, 2013
Benzinga Market Primer: Tuesday, May 7 - Benzinga
May 7, 2013
Broker Recommendations
| Current ABR | 1.13 |
| ABR (Last Week) | 1.13 |
| # of recs in ABR | 8 |
| Average Target Price | 16.13 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 36 out of 155 |
